Alexandria Venture Investments has helped RNA drug developer Remix Therapeutics launch with seed and series A funding.
US-based small molecule drug developer Remix Therapeutics launched on Tuesday with $81m from investors including Alexandria Venture Investments (AVI), a vehicle for real estate investment trust Alexandria Real Estate Equities.
The funding consisted of a seed round backed by Atlas Venture, The Column Group and Arch Venture Partners, and a series A round led by healthcare investment firm Foresite Capital that featured commitments from AVI and all three seed investors.
Remix is developing small molecule therapies designed to address the…
